GLP-1 receptor agonists like semaglutide are being used off-label by healthy people hoping to slow ageing, despite limited evidence and unknown long-term risks.
Leerink Global Healthcare Conference 2026 March 10, 2026 10:40 AM EDTCompany ParticipantsBrian Lian - President, CEO ...
Cone snails deploy sophisticated venom cocktails to paralyse prey. Anthony King talks to the researchers harnessing these ...
Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...
Two withdrawals of recently submitted initial public offering (IPO) filings by drug developers, plus a dearth of new filings this month, suggest that the outlook for biopharma IPOs remains cloudy, ...
The drugs have names that sound like small planets: semaglutide, liraglutide, lixisenatide. Collectively, they belong to a class of glucagon-like peptide 1 (GLP-1) analogs that has reshaped the ...
According to Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight, the pharmaceutical industry is becoming more interested in targeted radiation therapy as a novel, promising cancer ...
The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing ...
From the original show and Fear, to Dead City and Daryl Dixon ...
The table below is a review of notable updates that occurred in February 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.
For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results